InnoGI Technologies (formerly The TIM Company)’s Post

💬 “Using FUST Lab.’s equipment to develop a drug delivery system for liver cancer treatment would be incredibly impactful,” said one customer at the World Biomaterials Congress (WBC) 2024, eager for a follow-up meeting. FUST LAB. participated in the 12th WBC in Daegu from May 26th to 31st with our revolutionary surfactant-free dispersion/emulsification equipment. This quadrennial conference attracted over 4,000 researchers from about 60 countries, creating a dynamic and diverse atmosphere. We had the privilege of connecting with professionals from Korea, Japan, China, the UK, Australia, the US, and Europe, representing fields such as biomaterials, pharmaceutical research, and medical universities. We were deeply honored to hear some other standout comments like: 🌟 “Very impressive!” 🌟 “Unbelievable!” 🌟 “I want to conduct a real demonstration test!” What’s Next❓ 🇯🇵 Tokyo, here we come! 🇯🇵 We're thrilled to announce our participation in the 26th INTERPHEX Week Tokyo from June 26th to 28th! As Asia's leading trade fair for the pharmaceutical and cosmetics industry, it’s a crucial part of our Go-To-Market (GTM) strategy. I'm excited to meet potential customers at INTERPHEX and witness their reactions to our innovations. To ensure we maximize every opportunity, we've meticulously reviewed 1,000 exhibitors, refined our list to 400 companies, and further focused on 100 promising prospects. Can’t wait to see you all there! Let’s innovate and create impactful solutions together. 🌟 #FUSTLAB #WBC2024 #Biomaterials #PharmaceuticalInnovation #INTERPHEXTokyo #GlobalExpansion #Biotech #Innovation

#Wrapup, fresh from the press! After concluding the second and final day at the #SwissBiotechDay congress, we've got three key takeaways for AlveoliX , the community, and of course, the industry: ✅ Organs-on-a-Chip are shaking up the industry, with a strong interest in complementing in-vivo research with alternative modalities during discovery. 💡 Why? To detect toxicity in patient models much earlier or later in the drug development process. ✅ In these financially challenging times, pharmaceutical companies are seeking alternatives to reduce costs while maintaining quality. 💡AlveoliX Organ-on-a-Chip models meet this industry's needs. ✅We'll keep collaborating with our clients and empowering them to advance their molecular leads. That's all for now but get ready to catch the AlveoliX team at the next 3R LÄND Conference in Tübingen, Germany, May 21-23, 2024. Cheers and stay tuned! Picture: Daniel. A. Gutierrez and some empty chairs (While some people have already left, Daniel stayed behind to compile this summary for us) 😉. This year Swiss Biotech Days were an extraordinary dynamic and vital. A big compliment to the team around Michael Altorfer🤙. It is always great to welcome and meet our friends&family in Switzerland. Swiss Biotech Association InSCREENeX GmbH CSEM InSphero Jordi Xapelli Yemi AdesokanGnubiotics Sciences SA sitem-insel AG University of Bern CSL BioIVT and many many more.

Dive into Australia’s biotech ecosystem at #BIOHK2024! Get ready for insights and engaging discussions with members of the Australian Biotech Mission 2024. Join us to successfully start your next clinical trial with our #australianadvantage! Taking place between September 11-14, this year's event will feature discussions on cutting-edge biotech developments, raise awareness of innovative research and products, and inspire interaction and engagement to foster new collaborations. For 360biolabs, this event provides us with another valuable opportunity to promote the advantages of the Australian life sciences ecosystem, with our partners in our mission Acclime, Adjutor Healthcare Group, Alithia Life Sciences, Nucleus Network, SYNthesis BioVentures and TrialKey, sponsored by APAC Financial Services. You can find us at Booth # A1-2, E1-2, located at Hall 3DE within the Convention Centre. If you’re attending BIOHK2024 and want to discover how we can support your biopharmaceutical goals, let’s meet!  Connect with Angela Luttick, Sharon S., and Han Li, reach out to us at bd@360biolabs.com, message us on the partnering platform, or here on LinkedIn to schedule a one-on-one meeting.    Looking forward to engaging with you and exploring new opportunities together!    #360biolabs #bioanalyticallab #theaustralianadvantage #BIOHK #AustralianDelegation #BioTechOpportunities #biotechnology #lifesciences

Good morning lark chronotypes 🐦 🌄 Today is the first day of my favorite season. For me, autumn is a time when I can fully appreciate the warmth of my own home, and the long fall evenings are conducive to developing or deepening interests and making plans for the future. I come today precisely for the #future! There are many factors that determine the future, and one of the most important in the #biopharma industry is choosing the right partner to work with 🤝 Bringing drugs to market is cosmically expensive and complicated, and doing it yourself takes years, but I'm throwing you a lifeline in this case. #Collaboration with a biologics #CDMO offers numerous advantages for biopharma companies. Here are key reasons of their importance: ▶ Many companies face manufacturing limitations and Mabion S.A. offers spare capacity ▶ Our collaborative approach fosters open communication and trust to achieve goals more effectively ▶ We tailor our offerings to meet specific project needs, increasing productivity and efficiency with a faster time to market ▶ Mabion grants partners access to expertise and experience ▶ Awareness of adapting to changing market requirements is essential to driving cooperation ▶ We treat each project as if it were our own child through commitment and attention to detail in its maturation If you would like to learn how we combine the advantages listed above with high quality from gene to vial and a full analytical or release panel, I invite you to schedule a meeting with us at the upcoming CPHI Milan: https://lnkd.in/drYA8cGy

The life-science ecosystem of Wallonia (Southern Belgium) was showcased at the LSX World Congress by a panel of experts: Benoit Kenda, VP and Early Solution Partnering Head at UCB; Amel Tounsi, CEO of Bridge to Health; and Marc Foidart, Executive Chairman of EyeD Pharma. They offered a fresh perspective on the current investment and partnering landscapes within Europe, with a focus on Wallonia, Belgium. Find out more on the strategies and challenges involved in scaling up biotech innovations, the strengths and characteristics of Belgium and Wallonia's biotech ecosystem and the benefits and advantages to forming new partnerships within Belgium and the Walloon region. We are proud to have our life sciences ecosystem represented by such an impressive group of experts! UCB Bridge to Health (B2H) EyeD Pharma Wallonie Bruxelles International AWEX UK Wallonie-Bruxelles International - Research and Innovation Noshaq Pascale Delcomminette Bioxodes convEyXO EXO Biologics CorQuest MedTech Allyfe Gabi SmartCare Bio-Sourcing ODIX medical Amyl Therapeutics Bloomlife Inc neuroClues #biotech #innovation #investment #healthtech #healthcarerevolution #lifesciences

Meet Quotient at Swiss Biotech Day! Quotient Sciences is a drug development and manufacturing accelerator - providing integrated programs and tailored services across the entire development pathway. They cut through silos across a range of drug development capabilities - saving precious time and money in getting drugs to patients. E Their approach is clear: ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast. 

Patient-specific DILI causality assessments in clinical studies using the power of the MetaHeps assay !

Patient-specific DILI Causality Assessments using the power of the MetaHeps assay !

Come and join Yu-Su Chen and learn more about our NanoSight Pro and what it can do in terms of analysing extra cellular vesicles!